SeaStar Medical Raises $3.3M via Warrant Exercise
Event summary
- SeaStar Medical exercised warrants for 854,002 shares at a reduced price of $3.866 per share, raising $3.3M gross.
- The warrants were originally issued in June, July, and August 2025 with exercise prices ranging from $6.38 to $7.62.
- In exchange, SeaStar issued new warrants for up to 1,708,004 shares at $3.616 per share.
- Proceeds will be used for general corporate purposes, including working capital and capital expenditures.
- The offering is expected to close on October 5, 2026.
The big picture
SeaStar Medical's warrant exercise underscores its focus on securing non-dilutive financing to support its commercial-stage operations. The move comes as the company advances its SCD therapy through pivotal trials, aiming to address critical unmet needs in acute kidney injury. The $3.3M raise, though modest, provides a financial buffer amid the high costs of clinical development and regulatory approvals in the biotech sector.
What we're watching
- Financial Flexibility
- How SeaStar Medical will allocate the $3.3M proceeds to support its operations and growth initiatives.
- Market Conditions
- Whether the reduced exercise price reflects broader market challenges or strategic adjustments.
- Regulatory Pathway
- The pace at which SeaStar Medical advances its NEUTRALIZE-AKI trial and secures additional FDA approvals.
Related topics
